C. Joseph Ross Daval, Brigham and Women’s Hospital and Harvard University, Boston, Massachusetts. Ameet Sarpatwari, Brigham and Women’s Hospital and Harvard University. Aaron S. Kesselheim ([email ...
Cytokinetics recently announced that MYQORZO (aficamten), a cardiac myosin inhibitor for adults with symptomatic obstructive hypertrophic cardiomyopathy, is now commercially available in the U.S. via ...
JERSEY CITY, N.J., January 17, 2026--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced ...
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO™ (aficamten) is now available for prescription in 5 mg, 10 mg, 15 ...
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque Organon (NYSE: OGN), a ...
The U.S. Food and Drug Administration (FDA) has approved a label expansion for Nexplanon to allow its manufacturer, Organon (OGN), to market the birth control implant, indicating an efficacy duration ...
Travere Therapeutics is focused on rare kidney diseases, with FILSPARI driving significant revenue growth in IgA Nephropathy (IgAN). Competition in IgAN from larger players like Novartis and Vertex is ...
Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results